Recent data with anti-epidermal growth factor receptor antibodies and irinotecan in colon cancer

Clinical Colorectal Cancer

Volumn 5, Issue SUPPL. 2, 2005, Pages

  Yu, Jo Chua ^a   Cunningham, David ^a  

^a ROYAL MARSDEN HOSPITAL   (United Kingdom)

Author keywords

Cetuximab; Matuzumab; Panitumumab

Indexed keywords

ANTINEOPLASTIC AGENT; CAMPTOTHECIN; CETUXIMAB; DRUG DERIVATIVE; EPIDERMAL GROWTH FACTOR RECEPTOR; IRINOTECAN; MONOCLONAL ANTIBODY; PANITUMUMAB;

COLON TUMOR; DRUG ANTAGONISM; HUMAN; MULTIMODALITY CANCER THERAPY; PATHOPHYSIOLOGY; PHYSIOLOGY; REVIEW;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CAMPTOTHECIN; COLONIC NEOPLASMS; COMBINED MODALITY THERAPY; HUMANS; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 53849131307     PISSN: 15330028     EISSN: None     Source Type: Journal    
DOI: 10.3816/CCC.2005.s.011     Document Type: Article

References (60)

1. American Cancer Society. Cancer Facts and Figures 2005. Atlanta, GA: American Cancer Society, 2005.
2. Grothey A, Sargent D, Goldberg RM, et al. Survival of patients with advanced colorectal cancer improves with the availability of fluorouracil-leucovorin, irinotecan, and oxaliplatin in the course of treatment. J Clin Oncol 2004; 22:1209-1214.
3. Tournigand C, Andre T, Achille E, et al. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol 2004; 22:229-237.
4. Rasheed ZA, Rubin EH. Mechanisms of resistance to topoisomerase I-targeting drugs. Oncogene 2003; 22:7296-7304.
5. Xu Y, Villalona-Calero MA. Irinotecan: mechanisms of tumor resistance and novel strategies for modulating its activity. Ann Oncol 2002; 13:1841-1851.
6. Rivory LP. Irinotecan (CPT-11): a brief overview. Clin Exp Pharmacol Physiol 1996; 23:1000-1004.
7. Mathijssen RH, van Alphen RJ, Verweij J, et al. Clinical pharmacokinetics and metabolism of irinotecan (CPT-11). Clin Cancer Res 2001; 7:2182-2194.
8. Pizzolato JF, Saltz LB. The camptothecins. Lancet 2003; 361:2235-2242.
9. Cunningham D, Pyrhonen S, James RD, et al. Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer. Lancet 1998; 352:1413-1418.
10. Rougier P, Van Cutsem E, Bajetta E, et al. Randomised trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer. Lancet 1998; 352:1407-1412.
11. Rothenberg ML, Cox JV, DeVore RF, et al. A multicenter, phase II trial of weekly irinotecan (CPT-11) in patients with previously treated colorectal carcinoma. Cancer 1999; 85:786-795.
12. Saltz LB, Cox JV, Blanke C, et al. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. N Engl J Med 2000; 343:905-914.
13. Douillard JY, Cunningham D, Roth AD, et al. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet 2000; 355:1041-1047.
14. Rothenberg ML, Meropol NJ, Poplin EA, et al. Mortality associated with irinotecan plus bolus fluorouracil/leucovorin: summary findings of an independent panel. J Clin Oncol 2001; 19:3801-3807.
15. Arteaga CL. Overview of epidermal growth factor receptor biology and its role as a therapeutic target in human neoplasia. Semin Oncol 2002; 29:3-9.
16. Yarden Y, Sliwkowski MX. Untangling the ErbB signalling network. Nat Rev Mol Cell Biol 2001; 2:127-137.
17. Spano JP, Lagorce C, Atlan D, et al. Impact of EGFR expression on colorectal cancer patient prognosis and survival. Ann Oncol 2005; 16:102-108.
18. Goldstein NS, Armin M. Epidermal growth factor receptor immunohistochemical reactivity in patients with American Joint Committee on Cancer Stage IV colon adenocarcinoma: implications for a standardized scoring system. Cancer 2001; 92:1331-1346.
19. Radinsky R, Risin S, Fan D, et al. Level and function of epidermal growth factor receptor predict the metastatic potential of human colon carcinoma cells. Clin Cancer Res 1995; 1:19-31.
20. Karameris A, Kanavaros P, Aninos D, et al. Expression of epidermal growth factor (EGF) and epidermal growth factor receptor (EGFR) in gastric and colorectal carcinomas. An immunohistological study of 63 cases. Pathol Res Pract 1993; 189:133-137.
21. Kluftinger AM, Robinson BW, Quenville NF, et al. Correlation of epidermal growth factor receptor and c-erbB2 oncogene product to known prognostic indicators of colorectal cancer. Surg Oncol 1992; 1:97-105.
22. Steele RJ, Kelly P, Ellul B, et al. Epidermal growth factor receptor expression in colorectal cancer. Br J Surg 1990; 77:1352-1354.
23. Ciardiello F. Epidermal growth factor receptor tyrosine kinase inhibitors as anticancer agents. Drugs 2000; 60(suppl 1):25-32.
24. Waksal HW. Role of an anti-epidermal growth factor receptor in treating cancer. Cancer Metastasis Rev 1999; 18:427-436.
25. Huang SM, Bock JM, Harari PM. Epidermal growth factor receptor blockade with C225 modulates proliferation, apoptosis, and radiosensitivity in squamous cell carcinomas of the head and neck. Cancer Res 1999; 59:1935-1940.
26. Ye D, Mendelsohn J, Fan Z. Augmentation of a humanized anti-HER2 mAb 4D5 induced growth inhibition by a human-mouse chimeric anti-EGF receptor mAb C225. Oncogene 1999; 18:731-738.
27. Wood RD, Mitchell M, Sgouros J, et al. Human DNA repair genes. Science 2001; 291:1284-1289.
28. Bandyopadhyay D, Mandal M, Adam L, et al. Physical interaction between epidermal growth factor receptor and DNA-dependent protein kinase in mammalian cells. J Biol Chem 1998; 273:1568-1573.
29. Baselga J, Norton L, Masui H, et al. Antitumor effects of doxorubicin in combination with anti-epidermal growth factor receptor monoclonal antibodies. J Natl Cancer Inst 1993; 85:1327-1333.
30. Overholser JP, Prewett MC, Hooper AT, et al. Epidermal growth factor receptor blockade by antibody IMC-C225 inhibits growth of a human pancreatic carcinoma xenograft in nude mice. Cancer 2000; 89:74-82.
31. Fan Z, Baselga J, Masui H, et al. Antitumor effect of anti-epidermal growth factor receptor monoclonal antibodies plus cisdiam-minedichloroplatinum on well established A431 cell xenografts. Cancer Res 1993; 53:4637-4642.
32. Bruns CJ, Harbison MT, Davis DW, et al. Epidermal growth factor receptor blockade with C225 plus gemcitabine results in regression of human pancreatic carcinoma growing orthotopically in nude mice by antiangiogenic mechanisms. Clin Cancer Res 2000; 6:1936-1948.
33. Prewett MC, Hooper AT, Bassi R, et al. Enhanced antitumor activity of anti-epidermal growth factor receptor monoclonal antibody IMC-C225 in combination with irinotecan (CPT-11) against human colorectal tumor xenografts. Clin Cancer Res 2002; 8:994-1003.
34. Ciardiello F, Bianco R, Damiano V, et al. Antitumor activity of sequential treatment with topotecan and anti-epidermal growth factor receptor monoclonal antibody C225. Clin Cancer Res 1999; 5:909-916.
35. Inoue K, Slaton JW, Perrotte P, et al. Paclitaxel enhances the effects of the anti-epidermal growth factor receptor monoclonal antibody ImClone C225 in mice with metastatic human bladder transitional cell carcinoma. Clin Cancer Res 2000; 6:4874-4884.
36. Bianco C, Bianco R, Tortora G, et al. Antitumor activity of combined treatment of human cancer cells with ionizing radiation and anti-epidermal growth factor receptor monoclonal antibody C225 plus type I protein kinase A antisense oligonucleotide. Clin Cancer Res 2000; 6:4343-4350.
37. Milas L, Mason K, Hunter N, et al. In vivo enhancement of tumor radioresponse by C225 antiepidermal growth factor receptor antibody. Clin Cancer Res 2000; 6:701-708.
38. Saleh MN, Raisch KP, Stackhouse MA, et al. Combined modality therapy of A431 human epidermoid cancer using anti-EGFr antibody C225 and radiation. Cancer Biother Radiopharm 1999; 14:451-463.
39. Rubin M, Shin D, Pasmantier M, et al. Monoclonal antibody (MoAb) IMC-C225, an anti-epidermal growth factor receptor (EGFr), for patients (Pts) with EGFr-positive tumors refractory to or in relapse from previous therapeutic regimens. Proc Am Soc Clin Oncol 2000; 19:474a (Abstract #1860).
40. Saltz L, Rubin M, Hochster H, et al. Cetuximab (IMC-C225) plus irinotecan (CPT-11) is active in CPT-11 refractory colorectal cancer (CRC) that expresses epidermal growth gactor receptor (EGFR). Proc Am Soc Clin Oncol 2001; 20:3a (Abstract #7).
41. Rosenberg AH, Loehrer PJ, Needle MN, et al. Erbitux (IMC-C225) plus weekly irinotecan (CPT-11), fluorouracil (5FU) and leucovorin (LV) in colorectal cancer (CRC) that expresses the epidermal growth factor receptor (EGFr). Proc Am Soc Clin Oncol 2002; 21:135a (Abstract #536).
42. Cunningham D, Humblet Y, Siena S, et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 2004; 351:337-345.
43. Saltz L, Lenz HJ, Kindler H, et al. Randomized phase II trial of cetuximab/ bevacizumab/irinotecan versus cetuximab/bevacizumab in irinotecan-refractory colorectal cancer. J Clin Oncol 2005; 23 (16 suppl):248s (Abstract #3508).
44. Saltz LB, Meropol NJ, Loehrer PJ Sr, et al. Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. J Clin Oncol 2004; 22:1201-1208.
45. Lenz HJ, Mayer RJ, Mirtsching B, et al. Consistent response to treatment with cetuximab monotherapy in patients with metastatic colorectal cancer. J Clin Oncol 2005; 23(16 suppl):255s (Abstract #3536).
46. Folprecht G, Lutz M, Seufferlein T, et al. Cetuximab and irinotecan/5-FU/FA (AIO) as first line treatment in metastatic colorectal cancer (mCRC): Final results and pharmacokinetic data of a phase I/IIa study. J Clin Oncol 2005; 23(16 suppl):281s (Abstract #3640).
47. Rougier P, Raoul JL, Van Laethem JL, et al. Cetuximab + FOLFIRI as first-line treatment for metastatic colorectal CA. J Clin Oncol 2004; 22(14 suppl):3513.
48. Sobrero A, Scheithauer W, Maurel J, et al. Cetuximab plus irinotecan for metastatic colorectal cancer (mCRC): Safety analysis fo the first 400 patients in a randomized phase III trial (EPIC). J Clin Oncol 2005; 23(16 suppl):266s (Abstract #3580).
49. Yang XD, Jia XC, Corvalan JR, et al. Development of ABX-EGF, a fully human anti-EGF receptor monoclonal antibody, for cancer therapy. Crit Rev Oncol Hematol 2001; 38:17-23.
50. Figlin RA, Belldegrun AS, Crawford J, et al. ABX-EGF, a fully human anti-epidermal growth factor receptor (EGFR) monoclonal antibody (mAB) in patients with advanced cancer: phase I clinical results. Proc Am Soc Clin Oncol 2002; 21:10a (Abstract #35).
51. Hecht JR, Patnaik A, Malik I, et al. ABX-EGF monotherapy in patients (pts) with metastatic colorectal cancer (mCRC): An updated analysis. J Clin Oncol 2004; 22(14 suppl):3511.
52. Malik I, Hecht JR, Patnaik A, et al. Safety and efficacy of panitumumab monotherapy in patients wiht metastatic colorectal cancer (mCRC). J Clin Oncol 2005; 23(16 suppl):251s (Abstract #3520).
53. Vanhoefer U, Tewes M, Rojo F, et al. Phase I study of the humanized antiepidermal growth factor receptor monoclonal antibody EMD72000 in patients with advanced solid tumors that express the epidermal growth factor receptor. J Clin Oncol 2004; 22:175-184.
54. Chung KY, Shia J, Kemeny NE, et al. Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry. J Clin Oncol 2005; 23:1803-1810.
55. Moroni M, Veronese S, Benvenuti S, et al. Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to antiEGFR treatment in colorectal cancer: a cohort study. Lancet Oncol 2005; 6:279-286.
56. Vallbohmer D, Zhang W, Gordon M, et al. Molecular determinants of cetuximab efficacy. J Clin Oncol 2005; 23:3536-3544.
57. Saltz L, Kies M, Abbruzzese JL, et al. The presence and intensity of the cetuximab-induced acne-like rash predicts increased survival in studies across multiple malignancies. Proc Am Soc Clin Oncol 2003; 22:204 (Abstract #817).
58. Perez-Soler R. Can rash associated with HER1/EGFR inhibition be used as a marker of treatment outcome? Oncology (Huntingt) 2003; 17:23-28.
59. Lynch TJ, Bell DW, Sordella R, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004; 350:2129-2139.
60. Ellis LM, Hoff PM. Targeting the epidermal growth factor receptor: an important incremental step in the battle against colorectal cancer. J Clin Oncol 2004; 22:1177-1179.